Almirall profit quadruples in 2025 as dermatology fuels growth push - Invezz# Almirall profit quadruples in 2025 as dermatology fuels growth push[Earnings reports]Author[Noris Soto]Feb 23, 2026, 15:00 PM- Europe accounts for 91% of total sales; US revenue falls.- Dermatology drives 60% of revenue, led by Illumetri.- Almirall profit jumps 357% to €46.2M in 2025 on strong sales.Almirall, a pharmaceutical firm based in Spain, [ended 2025 with a net profit of €46.2 million], which was 357% more than its 2024 pr ...

Core Insights - EpimAb Biotherapeutics has achieved its first Clinical Trial Application (CTA) filing through its partnership with Almirall, marking a significant milestone for the company [1] - Almirall has licensed EpimAb's FIT-Ig platform to develop bispecific antibodies, with the first candidate targeting IL-13 and OX-40L for atopic dermatitis expected to enter Phase 1 clinical trials in the first half of 2026 [2] - The FIT-Ig technology allows for the generation of bispecific antibodies using basic structural components of monoclonal antibodies, demonstrating the platform's versatility and potential for rapid drug development [3] Company Overview - EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific antibodies, leveraging its proprietary FIT-Ig and MAT-Fab platforms to advance a unique pipeline targeting cancer and autoimmune diseases [4]

Core Viewpoint - Ipsen has appointed Peter Guenter as a new Director on its Board, effective January 28, 2026, filling the vacancy left by Henri Beaufour [1][9]. Group 1: Appointment Details - Peter Guenter brings nearly 40 years of experience in the global pharmaceutical industry, having most recently served as CEO of Merck Healthcare from 2021 to 2025 [2]. - His previous roles include CEO at Almirall, where he focused on medical dermatology, and over 20 years at Sanofi, where he joined the Executive Committee in 2013 [2][3]. - Following this appointment, Ipsen's Board will consist of 14 directors, equally divided between men and women, including five independent directors and two employee representatives [3]. Group 2: Shareholder Meeting - A request for ratification of Peter Guenter's appointment will be presented at the next Shareholders' meeting, which will remain effective until the 2027 Shareholders' meeting [4]. Group 3: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [5]. - The company operates in over 40 countries and partners globally to deliver medicines to more than 100 countries [5].

Core Viewpoint - The TCE bispecific antibody sector is entering a "golden era" with significant growth potential and innovation opportunities in cancer and autoimmune disease treatments [2][9]. Company Overview - A new generation of bispecific antibody pioneer, "Anmai Biotech," is advancing its listing process on the Hong Kong Stock Exchange, with a focus on T cell engagers (TCE) to address unmet medical needs in cancer and autoimmune diseases [3][4]. - Anmai Biotech has developed a robust pipeline of products, including three clinical-stage candidates: core product EMB-01, key product EMB-06, and EMB-07, along with four preclinical TCE candidates [4]. Commercialization Strategy - Anmai Biotech demonstrates industry-leading commercialization capabilities and is a model for domestic innovative drug companies expanding internationally through the NewCo model, having secured over $2.1 billion in global licensing deals, ranking second in the TCE field [6][8]. - The NewCo model allows for higher upfront payments and better resource integration, enabling partnerships with top global players to maximize the value of innovative assets [6]. Key Collaborations - A notable collaboration involves EMB-06, with a potential total transaction value of $635 million, showcasing the company's strategic partnerships and rapid clinical development efforts [7]. - Anmai Biotech has also engaged in multiple high-value business development transactions, including a global licensing agreement with Juri Biosciences worth up to $210 million [8]. Market Outlook - The global TCE market is projected to grow from $400 million in 2020 to $3 billion in 2024, with an expected CAGR of 43.4% from 2024 to 2034, indicating a significant market opportunity for Anmai Biotech [9].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 EpimAb Biotherapeutics Inc. 岸邁生物科技有限公司 （「本公司」） （於開曼群島註冊成立的有限責任公司） EpimAb Biotherapeutics Inc. 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。閣下閱覽本文件，即代表閣下知 悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或承銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長註冊的本公 司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中 的資料作出任何投資決定； (b ...

Core Insights - Recordati, a global pharmaceutical company, has announced the appointment of Mike McClellan as the new Chief Financial Officer (CFO) effective January 1, 2026 [1][3] - McClellan brings nearly 30 years of experience in the pharmaceutical industry, having previously served as CFO at Almirall and held significant roles at Teva and Sanofi [2][3] - The CEO of Recordati expressed confidence in McClellan's expertise to drive the company's strategy of consistent growth and stakeholder engagement [3] Company Overview - Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, with operations in approximately 150 countries and over 4,500 employees [4] - The company focuses on providing treatments across specialty and primary care, as well as rare diseases, with a mission to empower individuals to live life to the fullest [4]

Core Viewpoint - The biotech sector presents high-risk, high-reward investment opportunities, particularly for companies like Absci, which has a market cap of $600 million [1] Company Overview - Absci operates at the intersection of AI and biotechnology, leveraging machine learning and automation for drug discovery and development [2] - The company is positioned to lead a new generation of therapeutics, but its early-stage status and execution risks must be considered [2] Drug Discovery and Pipeline - Absci utilizes generative AI to model and design new therapeutics, potentially shortening R&D timelines [3] - The company has multiple drug candidates in clinical trials, including ABS-101 for IBD and ABS-201 for androgenic alopecia, with ABS-101 having launched a Phase 1 trial [3] Partnerships and Collaborations - Absci has established partnerships with major players in the biotech and pharma sectors, including a multi-year partnership with Merck valued at up to $610 million [4] - Other collaborations include partnerships with medical dermatology company Almirall and various firms [4] Market Potential - The AI drug discovery market is projected to grow at a CAGR of nearly 30% from 2024 to 2030, reaching over $20 billion [5] - Absci's addressable market includes biologics, monoclonal antibodies, and therapeutic proteins, indicating significant growth potential [5] Financial Position - Absci raised approximately $64 million in July 2025, increasing its cash reserves to over $117 million, providing a financial runway into 2028 [6] - The company is well-positioned to attract strategic investments as demand in the AI biotech space grows [6] Risks and Challenges - Absci faces execution and clinical risks, with no commercialized therapies currently available [7] - The company relies on research collaborations for revenue generation, which may concern investors [7] - The competitive landscape includes numerous rivals and legacy pharma players expanding their AI capabilities, adding uncertainty to Absci's growth [8] Analyst Sentiment - Analysts are generally optimistic about Absci, with six out of seven assigning a Buy rating and forecasting an upside potential of over 110% [9]

Company Overview - Absci Corporation (NASDAQ:ABSI) was founded in 2018 and is headquartered in Seattle, focusing on integrating deep learning with high-throughput lab automation for biologics design and optimization at scale [2] - The company utilizes its Integrated Drug Creation (IDC) platform, which combines proprietary algorithms with protein engineering to rapidly develop antibody and enzyme candidates for pharmaceutical partners and its own pipeline [2] Recent Developments - Absci recently expanded its partnership with Almirall, launching a second program targeting chronic skin diseases, which builds on the successful delivery of an AI-designed antibody [3] - The company appointed experts Dr. Rodney Sinclair and Dr. David Goldberg to advise on ABS-201, an AI-designed therapy for hair loss disorders, expected to enter clinical evaluation in early 2026 [3] Technological Advancements - Absci announced collaborations with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery capabilities [4] - The partnership with AMD includes a strategic investment, providing access to advanced chip technology and cloud resources for scaling model training and data processing [4] Financial Position - Absci secured $64 million in equity financing during July and August 2025, extending its operational runway through mid-2028 [5] - The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation's AI infrastructure for next-generation drug discovery [5]

Core Insights - Absci Corporation has strengthened its balance sheet by raising approximately $64 million in gross proceeds in July 2025, ensuring sufficient cash, cash equivalents, and short-term investments to fund operations into the first half of 2028 [1][7][11] - The company has expanded its collaboration with Almirall, electing a second target focused on dermatological indications, following the successful delivery of AI-designed functional antibodies [5][2] - The ongoing clinical trials for ABS-101 and ABS-201 are progressing, with key milestones anticipated in the near future [2][5] Financial Performance - For the second quarter of 2025, Absci reported revenue of $0.6 million, a decrease from $1.3 million in the same period of 2024 [8] - Research and development expenses increased to $20.5 million in Q2 2025 from $15.3 million in Q2 2024, driven by advancements in internal programs [9] - Selling, general, and administrative expenses decreased to $8.5 million in Q2 2025 from $9.3 million in Q2 2024, primarily due to a reduction in stock compensation expense [10] - The net loss for Q2 2025 was $30.6 million, compared to a net loss of $24.8 million in Q2 2024 [10] Pipeline and Collaborations - ABS-101 is currently in a Phase 1 clinical trial, with interim data readout expected in the second half of 2025 [5][6] - ABS-201, targeting androgenetic alopecia, is on track to enter clinical trials in early 2026, with an interim efficacy readout anticipated in the second half of 2026 [5][6] - The collaboration with AMD aims to scale Absci's AI Drug Creation platform, supported by a $20 million strategic equity investment from AMD [5] Asset Overview - As of June 30, 2025, Absci's cash, cash equivalents, and short-term investments totaled $117.5 million, down from $134.0 million as of March 31, 2025 [11] - The company has a total asset value of $209.9 million as of June 30, 2025, with total liabilities of $36.5 million [20][21]

Group 1 - The core agreement involves a strategic collaboration between Xiansheng Pharmaceutical's subsidiary Xiansheng Zaiming and US biopharmaceutical company NextCure for the development and commercialization of the antibody-drug conjugate (ADC) SIM0505, targeting CDH6, with a total potential payment of up to $745 million [2][5] - SIM0505 is positioned as a novel ADC with a proprietary TOPO inhibitor payload, showing strong anti-tumor effects in preclinical studies and a high systemic clearance rate, indicating potential for an expanded therapeutic window [3][4] - The collaboration includes a unique bidirectional technology partnership, allowing NextCure to utilize Xiansheng Zaiming's proprietary ADC linker and TOPO inhibitor payload for its own ADC development, while Xiansheng Zaiming retains rights for this new ADC in Greater China [4] Group 2 - The $745 million deal marks a significant milestone in Xiansheng Pharmaceutical's strategy for international expansion and highlights the successful global outreach of Chinese innovative drugs through business development (BD) models [5] - The collaboration underscores the international recognition of Chinese pharmaceutical companies' capabilities in cutting-edge technologies like ADCs, with Xiansheng Zaiming's proprietary payload being noted for its potential superior safety and efficacy compared to other topoisomerase inhibitors [5][6] - In recent years, Xiansheng Pharmaceutical has secured over $2.3 billion in potential transaction value through three overseas licensing agreements for self-developed innovative drugs, indicating a proactive shift towards globalizing Chinese original drugs [5]